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1ABSTRACT
Validation of a quantitative 12-multigene expression assay 
(Oncotype DX® colon cancer assay) in Korean patients 
with stage II colon cancer: implication of ethnic differences 
contributing to differences in gene expression
Duck Hyoun Jeong
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Nam Kyu Kim)
Purpose: To evaluate the Recurrence Score® of the quantitative 12-multigene 
expression assay and to determine risk groups based on the continuous 
Recurrence Score® in Korean patients. 
Method: A total of 95 patients with pathological T3N0 tumors and mismatch 
repair-proficient tumors were enrolled. The Recurrence Score® was used to 
classify risk groups (low risk, <30; intermediate risk, 30–40; high risk, ≥41).
Results: Fifty-four patients (56.8%) were aged over 70 years. There were 49 
men (51.6%) and 56 cases of right-sided colon cancer (58.9%). Eight cases 
(8.4%) had well-differentiated tumors, and 86 cases (90.5%) showed moderate 
differentiation. Only one case (1.1%) had a poorly differentiated tumor. Three 
patients (3.2%) had lymphovascular invasion. Sixty-one patients were identified 
as low risk (64.2%) and 34 patients as intermediate risk (35.8%). There were no 
high-risk patients. Although not significant, the 3-year recurrence risk increased 
with the Recurrence Score®.
Conclusion: Distribution patterns of risk groups based on the Recurrence 
Score®, particularly the absence of a high-risk group, were different from the 
prior validation studies. These findings suggest that ethnic differences between
Koreans and Western patients are potential contributing factors for different 
gene expressions in the quantitative 12-multigene expression assay.
----------------------------------------------------------------------------------------------
Key words : colonic neoplasms, gene expression, ethnic groups
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(Oncotype DX® colon cancer assay) in Korean patients 
with stage II colon cancer: implication of ethnic differences 
contributing to differences in gene expression
Duck Hyoun Jeong
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Nam Kyu Kim)
I. INTRODUCTION
Colorectal cancer (CRC) is the third most common malignancy in the world.1
In Asia, including Korea, CRC is currently the fourth leading cause of mortality 
by cancer, and its prevalence is increasing.2 After curative-intent resection of 
colon cancer, adjuvant therapy is performed to eliminate any potential source of 
disease recurrence. The benefits of adjuvant chemotherapy have been widely 
proven for stage III colon cancer; thus, it has become a standard treatment for 
such cases. However, the role of adjuvant chemotherapy remains less clear in 
patients with stage II colon cancer.3–5
Outcomes of stage II colon cancer vary;6,7 accordingly, risk stratification 
within stage II disease has been performed using clinical and pathologic 
variables. The current National Comprehensive Cancer Network guidelines 
recommend adjuvant chemotherapy for stage II colon cancer when patients have 
a pathological (p)T4 lesion, intestinal perforation or obstruction, lympho-
vascular invasion, perineural invasion, poorly differentiated histology, or fewer 
than 12 lymph nodes examined.8 However, there are no convincing data to 
predict the recurrence risk accurately for stage II disease. Thus, it is necessary 
to identify more effective predictors that can be used in addition to the 
traditional clinicopathologic parameters to assist in recurrence risk stratification 
and treatment decision-making for patients with stage II colon cancer.
Multiple-gene analysis can provide more reliable insight into tumor biology 
than single-gene analysis, and it can also yield more robust information 
regarding each prognosis, diagnosis, and response to treatment. In recent years, 
3several groups have developed multigene panel assays to determine the 
prognosis of patients with stage II colon cancer.9–11 One of these assays is the 
Oncotype DX® Colon Cancer Assay (Genomic Health, Redwood City, CA, 
USA), which utilizes a quantitative reverse transcription-polymerase chain 
reaction (RT-PCR)-based panel test using 12 genes. This panel was validated as 
a significant predictor for recurrence in stage II colon cancer.12–14
Most validation studies have been performed in Western countries;12–14
however, Ollberding et al15 suggested that ethnic difference may contribute to 
CRC risk through genetic susceptibility in their multiethnic cohort study. Thus, 
we postulated that gene expression patterns of the quantitative 12-multigene 
expression assay could differ between Western and Korean patients. The 
purpose of this pilot study was to investigate 1) the Recurrence Score® of the 
quantitative 12-multigene expression assay in Korean patients with stage II 
colon cancer and 2) the association between recurrence risk and the Recurrence 
Score® of the quantitative 12-multigene expression assay.
II. MATERIALS AND METHODS
1. Patients and materials
This study included a retrospective study (n=56) and a prospective study 
(n=39). Eligibility criteria for the retrospective study was as follows: Korean 
patients with biopsy-proven adenocarcinoma derived from the colon who 
underwent curative resection for colon cancer from January 2008 to 
December 2010; a postoperative pathologic report of American Joint 
Committee on Cancer stage II colon cancer with mismatch repair (MMR) 
gene-proficiency (low or stable microsatellite instability); no adjuvant 
chemotherapy; and available freshly frozen tumor tissues. Exclusion criteria 
were high-risk features, including the presence of a pT4 lesion, MMR 
gene-deficiency (high microsatellite instability),16 and a lack of freshly 
frozen tumor tissue. We obtained freshly frozen tumor tissue samples and 
complete medical records of 56 patients who satisfied the eligibility criteria. 
Age, sex, tumor location, and evidence of bowel obstruction or perforation 
were obtained from clinical records. Events of recurrence were included as 
local and systemic recurrences. Local recurrence was defined as tumor 
regrowth in the vicinity of the primary tumor site, and systemic recurrence 
was defined as tumor recurrence in the distant organs. We used all fresh 
frozen samples, and this methodology differed from that used in the original 
study, which used fixed paraffin-embedded tissue samples. Unfortunately, 
4we did not compare RNA quality between paraffin-embedded tissue and 
fresh frozen tissue samples. However, it has been reported that fresh frozen 
tissue preserves histologic cellular architecture and generates good-quality 
RNA.17
The prospective study enrolled 39 patients from January to December 
2012 using the same eligibility criteria as were used for retrospective 
enrollment. Patients who provided written informed consent were enrolled, 
and this study was approved by the institutional review board of Yonsei 
University Health System (number 4-2011-0888). The tumor tissues were 
stored in the Severance Hospital Gene Bank, which has been in operation 
since 2005. Tumor samples were obtained within 1 hour after surgical 
resection, transferred to the Gene Bank immediately, and frozen with liquid 
nitrogen. Specimens were stored at -80°C until further processing.
2. Recurrence Score®
The 12-multigene Recurrence Score® was calculated using the prespecified 
genes and algorithm that were previously validated12 and recognized cutoff 
points for low-, intermediate-, and high-recurrence risk groups (Recurrence 
Scores of <30, 30–40, and ≥41, respectively).
3. Endpoints
The primary endpoint was to evaluate the Recurrence Score® of the 
quantitative 12-multigene expression assay and to determine risk groups 
based on a continuous Recurrence Score® in Korean patients with stage II 
colon cancer. The secondary end point was to evaluate the relationship 
between the continuous Recurrence Score® and the 3-year recurrence risk.
4. Histopathologic data
Tumor grade and type were centrally assessed according to the College of 
American Pathologists Consensus Statement by an academic surgical 
pathologist with subspecialty expertise in gastrointestinal pathology.18 Data 
for pathologic T stage, number of nodes examined, lymphovascular invasion, 
perineural invasion, and histologic grade were recorded. MMR gene status 
was assessed in accordance with the consensus definitions of the National 
Cancer Institute, as previously described.19
55. Gene expression analysis 
A. RNA extraction 
Total RNA extraction was performed using TRIzol® reagent according to 
the manufacturer’s instructions (Life Technologies, Carlsbad, CA, USA). 
After RNA isolation, total RNA was checked for the quantity, purity, and 
integrity of the 18S and 28S ribosomal bands. Total RNA concentration 
was determined using a Nanodrop spectrophotometer ND-1000 (Thermo 
Fisher Scientific, Waltham, MA, USA). For each sample quantity tested, 
RNA degradation was assessed using the Agilent Bioanalyzer 2100 
(Agilent Technologies, Santa Clara, CA, USA) (Figure 1).
Figure 1. Total RNA quality control
Notes: (A) The total RNA sample is shown as 18s and 28s bands by 
electrophoresis on a 1% formaldehyde gel. (B and C) each sample was assessed 
for integrity using the Agilent Bioanalyzer 2100. The bioanalyzer software 
generates a gel-like image and an electropherogram. The RNA quality was 
determined by visual inspection of the electropherogram, 260/280 and 260/230 
ratio, concentrations, and the RIN.
Abbreviations: Cont, control; DX, sample number; RIN, RNA integrity number.
6B. Reverse transcription
The RT reaction was carried out with 1 μg of total RNA using the 
QuantiTect® Reverse Transcriptase Kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s instructions.
C. Quantitative PCR (qPCR) and gene-expression analysis
cDNA for target genes (BGN, MYC, FAP, GADD45B, INHBA, MK167, 
MYBL2, UBB) and reference genes (ATP5E, GPX1, PGK1, UBB, and 
VDAC2) was distributed into 96-well plates and PCR forward and 
reverse primer and TaqMan® probes were added. The TaqMan® probes 
and primers were designed as previously described.20 The primer and 
probe sequences used are presented in Table 1. Oligonucleotides were 
purchased from Cosmogenetech Co., Ltd. (Seoul, Korea). In this study, 
TaqMan probes had a fluorescein (6-FAM®) 5′-reporter and a Black Hole 
Quencher®-1 (BHQ-1®) 3′-quencher. qPCR was performed using a 
fluorescence-based real-time detection system (ABI PRISM 7000 
sequence detection system; Applied Biosystems, Foster City, CA, USA) 
according to the manufacturer’s instructions. Reactions were performed 
in a 25 μL volume with cDNA equivalent to 1 μg total RNA. The final 
primer and probe concentrations were 0.9 μmol/L (primers) and 0.25 
μmol/L (probes). PCR cycling conditions were 95°C for one cycle of 10 
minutes, followed by 43 cycles of 20 seconds at 95°C then 45 seconds at 
60°C. Each gene assay was run in triplicate wells.
Table 1. Sequences of TaqMan probes and PCR primers
Gene Oligo Sequence
ATP5E Forward CCGCTTTCGCTACAGCAT
Reverse TGGGAGTATCGGATGTAGCTG
Probe TCCAGCCTGTCTCCAGTAGGCCAC
BGN Forward GAGCTCCGCAAGGATGAC
Reverse CTTGTTGTTCACCAGGACGA
Probe CAAGGGTCTCCAGCACCTCTACGC
MYC Forward TCCCTCCACTCGGAAGGACTA
Reverse CGGTTGTTGCTGATCTGTCTCA
Probe TCTGACACTGTCCAACTTGACCCTCTT
FAP Forward CTGACCAGAACCACGGCT
Reverse GGAAGTGGGTCATGTGGG
Probe CGGCCTGTCCACGAACCACTTATA
GADD45B Forward ACCCTCGACAAGACCACACT
7Reverse TGGGAGTTCATGGGTACAGA
Probe AACTTCAGCCCCAGCTCCCAAGTC
GPX1 Forward GCTTATGACCGACCCCAA
Reverse AAAGTTCCAGGCAACATCGT
Probe CTCATCACCTGGTCTCCGGTGTGT
INHBA Forward GTGCCCGAGCCATATAGCA
Reverse CGGTAGTGGTTGATGACTGTTGA
Probe ACGTCCGGGTCCTCACTGTCCTTCC
MK167 Forward CGGACTTTGGGTGCGACTT
Reverse TTACAACTCTTCCACTGGGACGAT
Probe CCACTTGTCGAACCACCGCTCGT
MYBL2 Forward GCCGAGATCGCCAAGATG
Reverse CTTTTGATGGTAGAGTTCCAGTGATTC
Probe CAGCATTGTCTGTCCTCCCTGGCA
PGK1 Forward AGAGCCAGTTGCTGTAGAACTCAA
Reverse CTGGGCCTACACAGTCCTTCA
Probe TCTCTGCTGGGCAAGGATGTTCTGTTC
UBB Forward GAGTCGACCCTGCACCTG
Reverse GCGAATGCCATGACTGAA
Probe AATTAACAGCCACCCCTCAGGCG
VDAC2 Forward ACCCACGGACAGACTTGC
Reverse AGCTTTGCCAAGGTCAGC
Probe CGCGTCCAATGTGTATTCCTCCAT
Notes: The TaqMan probe consists of an oligonucleotide with a 5′-reporter dye 
(6-FAM®) and a 3′-quencher dye (BHQ®-1). Primers and probes shown were used 
for analysis of ATP5E. BGN, MYC, FAP, GADD45B, GPX1, INHBA, MK167, 
MYBL2, PGK1, UBB, and VDAC2
Abbreviations: PCR, Polymerase chain reaction; BHQ®-1, Black hole 
Quencher®-1; FAM, Fluorescein.
D. Reference gene normalization
Normalization was performed using the average expression of the five 
reference genes (ATP5E, GPX1, PGK1, UBB, and VDAC2). The mean 
cycle threshold (Ct) value for each gene was subtracted from the mean Ct 
for the five reference genes.20
6. Statistical analysis 
All data are described as frequency and percentage. Differences among 
groups were analyzed with the chi-square test or Fisher’s exact test. 
Univariate and multivariate Cox regression analyses were used to estimate 
the hazard ratio (HR) and 95% confidence interval (CI). A rug plot was 
8displayed to confirm the relationship between observed and predicted risk. 
All tests were two-sided, and a P-value of 0.05 was considered to be 
statistically significant. Statistical analyses were conducted using R project 
for Statistical Computing, Version 2.12.0 (R Development Core Team, 
Vienna, Austria) and SPSS software version 20.0 for Windows (SPSS Corp., 
Chicago, IL, USA).
III. RESULTS
   1. Demographics
Fifty-four patients (56.8%) were aged over 70 years and the mean age was 
69.6 years (range, 43–85). The patient group consisted of 49 (51.6%) men 
and 46 (48.4%) women. Fiftysix carcinomas (58.9%) were located in the 
right-sided colon, and 39 (41.1%) were in the left-sided colon. Eight cases 
(8.4%) had well-differentiated tumors, and 86 cases (90.5%) showed 
moderate differentiation. Only one case (1.1%) had a poorly differentiated 
tumor. Three patients (3.2%) had lymphovascular invasion (+) tumors and 
two patients (2.1%) had perineural invasion (+) tumors.
There were no differences in demographics between the retrospective and 
prospective cohorts except for the number of lymph nodes examined. In the 
retrospective cohort, nine patients (9.5%) had fewer than 12 harvested lymph 
nodes in the specimen; however, all patients had 12 or more nodes in the 
prospective cohort. Detailed demographics are summarized in Table 2.
Table 2. Patient demographics and cancer characteristics
Variables Total patients 
(N=95)
Retrospective 
cohort (N=56)
Prospective 
cohort (N=39)
P-value
N (%) N (%) N (%)
Age (≥70 years) 54 (56.8) 31 (55.4) 23 (59.0) 0.389
Sex (male) 49 (51.6) 30 (53.6) 19 (48.7) 0.681
Carcinoembryonic antigen (≥5 ng/ml) 24 (25.3) 14 (25.0) 10 (25.6) 1.000
Tumor location 0.407
Right/transverse colon 56 (58.9) 35 (62.5) 21 (53.8)
Left/sigmoid colon 39 (41.1) 21 (37.5) 18 (46.2)
Harvested lymph nodes (≥12) 86 (90.5) 47 (83.9) 39 (100) 0.010
Histologic differentiation 0.093
Well 8 (8.4) 7 (12.5) 1 (2.6)
Moderate 86 (90.5) 49 (87.5) 37 (94.9)
Poor 1 (1.1) 0 (0) 1 (2.6)
Lymphovascular invasion (+) 3 (3.2) 0 (0) 3 (7.7) 0.066
Perineural invasion (+) 2 (2.1) 0 (0) 2 (5.1) 0.087
9NCCN high-risk features (+)* 15 (15.8) 11 (19.6) 4 (10.3) 0.263
Recurrence (+) 4 (4.2) 4 (7.1) 0 (0) 0.141
Notes: *NCCN high-risk features are defined as number of harvested lymph nodes <12, histologically 
poorly differentiated, obstruction or perforation, lymphovascular invasion, perineural invasion, or 
positive margin.
Abbreviations: +, positive; NCCN, national comprehensive cancer network.
   2. Distribution of risk groups based on Recurrence Score®
The 12-multigene Recurrence Score® ranged from 0 to 39, with a median 
score of 28 (interquartile range, 20.3–31.8) and a mean of 23.3 (±11.4 
standard deviation). Risk groups were classified based on the calculated 
Recurrence Score® (low risk, <30; intermediate risk, 30–40; high risk, ≥41). 
Sixty-one patients were identified as low risk (64.2%) and 34 as 
intermediate risk (35.8%). There were no high-risk patients (Table 3).
Table 3. Distribution of risk groups and characteristics of validation studies using the Oncotype DX® Colon Cancer Assay 
Study Number of 
patients
Risk groups based on Recurrence Scores® Ethnicity (%) Age Sex Stage II 
(%)
pT4 stage 
(%)
High-grade 
tumor (%)
LN <12 
(%)
LVI 
(%)
MMR-p 
(%)Low (%) Intermediate (%) High (%) ≥70 (%) Male (%)
Gray et al12 1,436 311 (43.7) 218 (30.7) 182 (25.6) NA 24 58 100 15 31 35 14 87
Venook et al13 690 266 (41.0) 227 (35.0) 156 (24.0) White (92) 35 52 100 6 32 47 11 79
Yothers et al14 892 103 (39.0) 94 (35.6) 67 (25.4) White (88) 17 58 30 6 25 39 NA 88
Current study 95 611 (64.2) 34 (35.8) 0 (0.0) Korean (100) 57 52 100 0 1 10 3 100
Abbreviations: LN, lymph nodes; LVI, lymphovascular invasion; MMR-p, mismatch repair gene-proficient; NA, not available; p, pathological. 
3. Relationship between Recurrence Score® and recurrence risk
To evaluate the relationship between the continuous Recurrence Score® and 
the 3-year recurrence risk, we performed subgroup analyses in the 
retrospective cohort. The median follow-up time was 31 months. During 
the follow-up period, four patients (4.2%) developed recurrence. Three 
cases were in the low-risk group and one was in the intermediate-risk group 
(Table 4). 
Table 4. Four patients with recurrence
Case Pattern 
of failure
Recurrence 
Scores®
Age 
(years)
Sex CEA 
(ng/mL)
Tumor 
location
Tumor
stage
Histologic
grade
Number 
of LNs
LVI
Case 1 Local 1 73 Male 4.8 Right T3 MD 2 -
Case 2 Local 36 67 Male 3.4 Right T3 MD 24 -
Case 3 Systemic 21 50 Male 1.7 Left T3 MD 40 -
Case 4 Systemic 10 68 Female 3.5 Left T3 MD 20 -
Abbreviations: -, negative; LN, lymph nodes; LVI, lymphovascular invasion; MD, moderately differentiated; CEA, carcinoembryonic antigen.
In the primary analysis based on the Cox model, although not significant, 
the 3-year recurrence risk increased with the Recurrence Score® (HR per 
interquartile range, 0.52; 95% CI, 0.19–1.39; P=0.58; Figure 2).
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Figure 2. Relationship between the continuous Recurrence Score® and 3-year 
recurrence risk
Note: A rug plot depicting the distribution of the Recurrence Score® is included at 
the bottom of the figure.
Conventional clinical and pathologic factors including age, sex, tumor 
location, tumor grade, and number of lymph nodes did not show any significant 
associations with recurrence-free survival in the univariate and multivariate 
analyses using the Cox proportional hazard model. Similarly, risk assessment 
based on the National Comprehensive Cancer Network guidelines was not a 
significant risk factor for recurrence-free survival, with a HR of 1.41 (95% CI, 
0.15–13.58; P=0.767; Table 5).
Table 5. Prognostic factors for recurrence-free interval in the retrospective cohort (n=56)
Variables Univariate Multivariate
HR (95%CI) p-value HR (95% CI) p-value
Dichotomous
  Sex: female vs male 0.331 (0.034-3.181) 0.338 0.514 (0.045–5.919) 0.593
  Tumor location: right vs left-side 0.775 (0.109-5.514) 0.799 1.19 (0.085–16.614) 0.897
  Tumor grade: well vs moderate <0.001 (<0.001-999.9) 0.998 ,0.001 (,0.001–999.9) 0.999
  Nodes examined: <12 vs ≥12 1.929 (0.200-18.570) 0.570 1.98 (0.079–49.654) 0.678
  NCCN risk*: high vs low 1.41 (0.146-13.580) 0.767 1.223 (0.056–26.882) 0.899
Continuous
Age, years 0.959 (0.881–1.044) 0.335 0.96 (0.855–1.077) 0.485
Recurrence Score® per IQR 0.517 (0.193–1.390) 0.191 0.582 (0.203–1.672) 0.315
Notes: *NCCN high-risk features are defined as number of harvested lymph nodes <12, histologically poorly 
differentiated, obstruction or perforation, lymphovascular invasion, perineural invasion, or positive margin.
Abbreviations: CI, confidence interval; HR, hazard ratio; IQR, interquartile range; NCCN, National Comprehensive 
Cancer Network; vs, versus.
IV. DISCUSSION
We hypothesized that gene expression patterns of Korean patients may be 
11
different from those of Western patients. 
Thus, we determined gene expression using the quantitative 12-multigene 
expression assay, Recurrence Scores®, and risk groups (low, intermediate, or 
high risk). The distribution of risk groups based on Recurrence Score® showed 
that majority of patients (n=61, 64.2%) were in the low-risk group and the 
remaining were in the intermediate-risk group (35.8%). There were no high-risk 
patients. The distribution pattern of risk groups, particularly the absence of a 
high-risk group, was quite different from the published validation studies.12–14      
These results suggest that ethnic differences between Korean and Western 
patients may play a role in the observed differences in gene expression from the 
quantitative 12-multigene expression assay. However, we acknowledge that 
other underlying factors that were not considered in this study might have 
influenced differences in gene expression. In addition, the Recurrence Score®
predicted a recurrence risk in the previous validation studies,12–14 and we also 
found that, although not significant, Recurrence Score® was associated with an 
increased 3-year recurrence risk. The nonsignificant result could be attributed to 
the small study sample.
Detailed clinical and pathologic variables of major validation studies are 
summarized in Table 3. Upon a review of the literature, the distribution pattern 
of risk groups (notably the absence of high-risk patients in this study) differed 
from major validation studies, such as the QUASAR (Quick And Simple And 
Reliable) trial,12 CALGB (Cancer And Leukemia Group B) 9581 trial,13 and 
NSABP (National Surgical Adjuvant Breast and Bowel Project)-C07 study.14
The proportion of low-risk group patients was 39.0%–43.7% in the prior 
studies12–14 yet was 64.2% in this study. Additionally, the proportion of 
Caucasian patients (White race/ethnicity) was predominant (88%–92%) in the 
previous studies.13,14 Our results suggest that the genetic characteristics of CRC 
in Asian patients, particularly Koreans, are different from Western patients 
based on results of the quantitative 12-multigene expression assay for colon 
cancer.
In previous studies, the proportion of patients older than 70 years was 
17%–35%, and the rate of less than 12 lymph nodes ranged from 35% to 
47%;12–14 however, our study yielded corresponding results of 57% and 10%. 
Interestingly, high-grade tumors were much more uncommon (1%) in this study 
than in prior studies (25%–32%).12–14 Gray et al12 observed that high-grade 
tumors were more frequent in the high-risk group than in the low-risk group 
(44% vs 23%). The authors suggested that patients with higher Recurrence 
Score® were more likely to have T4 disease, MMR-deficient tumors, and 
12
high-grade tumors. It is possible that, by excluding those with T4 disease and 
those with MMR- deficient tumors, our sampling process excluded patients with 
high-grade tumors. The lower Recurrence Scores® in this study population 
might be attributable to the limited inclusion criteria. Thus, if we had included 
more high-grade tumors, the proportion of tumors in the high-risk group would 
likely have increased. However, it is possible that the absence or relatively low 
proportion of high-risk patients could be distinctive genetic characteristics of 
Korean patients found using the quantitative 12-multigene expression assay. 
Thus, the validation results of Western patients need to be cautiously applied to 
other ethnicities, including Korean patients.
In this study, only pT3N0 and MMR-proficient tumors were included in order 
to maintain a homogenous study population. MMR gene-deficiency, also called 
high microsatellite instability, is associated with a lower recurrence risk in stage 
II colon cancer and is unlikely to benefit from fluorouracil-based adjuvant 
chemotherapy.19,21,22 Ethnic differences of MMR-gene status have also been 
shown. Hong et al19 reported that rates of MMR gene-deficient tumors were 
~9% in Korean CRC patients and ~18% in Western patients.23,24 These 
differences in MMR gene status suggest that ethnic differences are associated 
with gene expression. Our finding based on results from the quantitative 
12-multigene expression assay also supports the hypothesis that ethnic 
difference is associated with gene expression difference.
Three validation studies, the QUASAR trial,12 CALGB 9581 trial,13 and 
NSABP-C07 study,14 showed that Recurrence Score® was significantly 
associated with recurrence risk in stage II12,13 or stage II and III patients.14 The 
prognostic significance of the 12-multigene expression assay has also been 
validated in rectal cancer patients. Reimers et al25 reported that Recurrence 
Score® was a significant predictor for recurrence risk and cancer-specific 
survivals in stage II and III rectal cancer patients. In this study, we also 
observed a similar pattern in that the 3-year recurrence risk increased with 
Recurrence Score®, although this association was not significant. Our study had 
only four events of recurrences; thus, if there were more recurrence events in 
our study population, we could expect a significant relationship between 
Recurrence Score® and recurrence risk.
The main limitations of this study were the small study population and the 
fact that there were only four recurrence events; thus, it was difficult to obtain 
meaningful results from the multivariate risk factor analysis for recurrence-free 
survival. In addition, this study did not include patients with rectal cancer, 
which has previously been associated with more frequent recurrences compared 
13
with colon cancer.26 However, it was the first study to investigate gene 
expression patterns based on the quantitative 12-multigene expression assay in 
Korean patients with colon cancer. In addition, our study population was 
relatively homogenous in that it included only T3N0 tumors and MMR
proficient tumors.
V. CONCLUSION
Distribution patterns of risk groups based on Recurrence Score®, especially 
absence of a high-risk group, were different from the results of prior validation 
studies.12–14 These findings suggest that ethnic differences between Korean and 
Western patients are potential contributing factors of differences in gene 
expression in the quantitative 12-multigene expression assay. In addition, 
although not significant, Recurrence Score® was associated with an increased 
3-year recurrence risk. Based on our findings, recurrence risk stratification 
based on the quantitative 12-multigene expression assay can be applied to 
Korean patients with stage II and MMR gene-proficient tumors. However, the 
results of the assay should be interpreted cautiously in Korean patients, as 
unidentified ethnic differences may exist in the gene expression pattern. 
Moreover, there might have been other factors involved in differences in gene 
expression in the quantitative 12-multigene expression assay that were not 
addressed in this study. We did not evaluate another cohort of a different 
ethnicity. Accordingly, it should be determined in future research whether 
ethnicity is the main reason for the differences in Recurrence Score® in other 
ethnic groups. In addition, definite conclusions could not be drawn in this study 
due to the limited sample size. In future perspectives, it would be useful to 
identify single-nucleotide polymorphisms affecting gene expression levels of 
genes included in the quantitative 12-multigene expression assay in a Korean 
population, and more genetic studies should be performed in order to validate 
exact ethnic differences in gene expression. 
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ABSTRACT(IN KOREAN)
한국인 대장암 2기 환자에서 정량적 12-다중유전자 검사
(Oncotype DXⓇ Colon Cancer Assay)의 유효성 분석 : 유전자
발현 차이에 기여하는 인종적 차이의 의미
<지도교수 김남규>
연세대학교 대학원 의학과
정   덕   현
목적: 한국인 대장암 2기 환자에서 정량적 12-다중유전자 검사의
재발점수에 대한 평가와 재발점수에 따른 재발 위험군을 선별하고자
한다.
방법: MMR-p 이면서 병리학적으로 T3N0인 95명의 환자를
대상하였으며, 재발 점수에 따라 30점 이하는 저위험군, 30-40점은
중간위험군, 40점 이상은 고위험군으로 분류하였다.
결과: 54명(56.8%)의 환자는 70세 이상이었으며, 49명(51.6%)는
남성이었으며, 56명(58.9%)는 우측대장암이었다. 8명(8.4%)이
고분화암이었고, 86명(90.5%)은 중간분화암, 1명(1.1%)만이
저분화암이었다. 3명(3.2%)에서 림프혈관강전이가 있었다. 재발점수에
따른 위험도 분류상 61명(64.2%)은 저위험군, 나머지 34명(35.8%)은
중간위험군이었으며 고위험군 환자는 없었다.
통계학적 유의성은 없었으나, 재발점수가 증가할수록 3년 재발율이
증가하는 추세를 보였다.
결론: 재발점수에 따른 위험군 분류상 고위험군이 존재하지 않는
것은 다른 이전의 유사한 검증 연구에서와는 다른 결과이다. 이러한
결과는 한국인과 서양인 환자 사이의 인종적 차이가 정량적
12-다중유전자 검사에서 서로 다른 유전자 발현을 하게 만드는
잠재적 기여 요인이 될 수도 있다는 것을n 암시한다.
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